SAN FRANCISCO, March 6, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced that Matthew R.
Patterson, President and Chief Executive Officer, will
present at the Cowen 38th Annual Health Care Conference
in Boston, MA. The
presentation is scheduled for Tuesday, March
13, 2018, at 10:00 am ET.
To access a live webcast of the presentation, please visit the
Events & Presentations page within the Investors + Media
section of the Audentes website. A replay of the live webcast
will be available on the Audentes website for approximately 30 days
following the conference.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on
developing and commercializing innovative gene therapy products for
patients living with serious, life-threatening rare diseases.
We are currently conducting Phase 1/2 clinical studies of our lead
product candidates AT132 for the treatment of X-Linked Myotubular
Myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar
Syndrome. We have two additional product candidates in
development, including AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
Catecholaminergic Polymorphic Ventricular Tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Paul Laland
415.519.6610
plaland@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-the-cowen-38th-annual-health-care-conference-300608180.html
SOURCE Audentes Therapeutics, Inc.